Piramal Enterprises plans to raise up to Rs 1,000 crore via NCDs

NEW DELHI: Piramal Enterprises Wednesday said it plans to raise up to Rs 1,000 crore through issue of secured non-convertible debentures (NCDs) on private placement basis. The administrative committee of the board approved issue of secured NCDs on private placement basis up to Rs 500 crore with an option to retain over-subscription of up to Rs 500 crore, aggregating the total issue size to Rs 1,000 crores in two series, the company said in a filing to the BSE.

The issue size of Series 1 is Rs 100 crore, it added.

The size of Series 2 is Rs 400 crore with green shoe option of Rs 500 crore, so that the total value shall not exceed Rs 900 crore, Piramal Enterprises said.

The company, however, did not specify what it wants to do with the funds to be raised.

Its shares were on Wednesday trading at Rs 2,271.05 per scrip on the BSE, down 0.48 per cent from its previous close.

  • Related Posts

    • Pharma
    • July 10, 2025
    • 100 views
    Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

    India stands tall as a pharmaceutical powerhouse, supplying 20% of the world’s generic medicines and nearly 62% of global vaccines. Yet, this success now faces a storm: US President Donald…

    • Pharma
    • July 10, 2025
    • 95 views
    Novartis wins approval for first malaria drug for newborns and babies

    ZURICH: Novartis (NOVN.S), opens new tab said on Tuesday it had received approval in Switzerland for Coartem Baby, which it said was the first drug to treat malaria in babies…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Very Arty Surgery for Weight Loss by SSI Mantra, World’s First

    Very Arty Surgery for Weight Loss by SSI Mantra, World’s First

    Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

    Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

    Novartis wins approval for first malaria drug for newborns and babies

    Novartis wins approval for first malaria drug for newborns and babies

    Nectar to sell API, formulations & menthol biz to Ceph Lifesciences for Rs 1,290 cr

    Nectar to sell API, formulations & menthol biz to Ceph Lifesciences for Rs 1,290 cr